Germany’s Startup Scorecard Looks Different When Your Startup Has Reactors, Not Just Laptops
The German Startup Verband has published its one‑year assessment of the federal government’s startup agenda. Many of the right headlines are there: more growth capital, a stronger role for the state as an anchor customer, better tech transfer. But for founders in industrial green chemistry and pharmaceutical manufacturing, the reality still looks very different. Their business models depend on pilot plants, process upgrades and public procurement – precisely the areas where implementation is slowest. This article takes the key findings of the report and asks what they mean if your startup builds cleaner chemistry, not just software.
NEWS
Angela Kroll
4/29/20262 min read
The same promises, a different reality for deeptech
Germany now has a long list of startup‑friendly commitments: more venture capital, more pension money in growth funds, faster procedures, better conditions for spin‑offs. On paper, this is positive.
In practice, founders in industrial green chemistry see a different picture. Their projects involve multi‑million euro capex, long validation cycles and strict regulation – but the tools designed to support them still look like they were built with SaaS in mind.
For these teams, the question is not only “Is there more capital?” but “Can we finance an actual plant upgrade, a first‑of‑a‑kind line or a green route for an essential ingredient?” Without that perspective, the most important part of the transition is left out.
Why the “state as anchor customer” is crucial for chemistry
The report rightly highlights the state’s role as an anchor customer – and criticises that recent procurement changes have not yet delivered the promised opening for startups. This is especially critical in chemistry‑related fields.
Public infrastructure, water utilities, hospitals and public labs are exactly where new processes, PFAS‑free treatment or greener active ingredients should be tested and scaled.
If procurement remains focused on lowest short‑term price and legacy frameworks, deeptech chemistry startups will continue to watch from the sidelines. A credible anchor‑customer strategy would include dedicated pilot tenders for green process technologies, clear innovation quotas, and evaluation criteria that reward lower emissions, better resource efficiency and supply security.
Financing plants, not just pitch decks
Another core message of the Startup Verband is the need to unlock more private capital and institutional investors. For industrial green chemistry, this is not a nice‑to‑have – it is a prerequisite for market entry.
Scaling a new synthesis, separation process or treatment technology rarely happens in a garage. It happens in reactors, pilot plants and existing industrial sites. Ticket sizes are larger, risks are different, and timelines don’t fit standard fund models.
This is why we argue that any serious growth‑capital agenda must explicitly consider chemistry and process innovation: blended finance for industrial pilots, guarantees for retrofit projects, and growth equity that accepts engineering risk, not just market risk.
Spin‑offs and IP: turning chemistry research into real plants
Germany’s chemistry and pharma research is internationally respected. Yet only a fraction of promising process innovations become independent companies or licensed industrial projects.
The Startup Verband calls for better transfer and more flexible IP rules. From an IGC perspective, this should include: clear, fast pathways for spinning out process IP, incentives for industrial testbeds, and frameworks that let founders and universities share risk and upside fairly.
Without this, the country will continue to publish strong papers on green chemistry while other regions build the plants.
Where IGC wants to add value
We see the Startup Verband’s one‑year report as an important benchmark for the overall ecosystem. Our role is to zoom in on one critical vertical: industrial green chemistry and process innovation in chemicals and pharma manufacturing.
The next step for Germany’s startup agenda is to make sure that these founders can actually build – in real facilities, with real procurement, inside real value chains.
That means:
growth capital that works for capex‑heavy projects,
procurement that gives new chemistry a fair shot,
and transfer mechanisms that turn research excellence into industrial reality.
Only then will the promise of a “startup‑friendly” Germany ring true for the people trying to decarbonise and modernise its chemical base.